본문으로 건너뛰기
← 뒤로

Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.

Clinical cancer research : an official journal of the American Association for Cancer Research 2026 CNS Lymphoma Diagnosis and Treatment
OpenAlex 토픽 · CNS Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research CAR-T cell therapy research

Chang KY, Hsu YT, Chuang SS, Hsiao CF, Huang TC, Hsieh CY, Yeh SP, Ma WL, Wang MC, Chen TY, Hsueh PR, Wu SJ

📝 환자 설명용 한 줄

[PURPOSE] Primary central nervous system lymphoma (PCNSL) has a poor prognosis and limited treatment options.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Kwang‐Yu Chang, Ya-Ting Hsu, et al. (2026). Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-25-3675
MLA Kwang‐Yu Chang, et al.. "Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.." Clinical cancer research : an official journal of the American Association for Cancer Research, 2026.
PMID 42018298

Abstract

[PURPOSE] Primary central nervous system lymphoma (PCNSL) has a poor prognosis and limited treatment options. This phase 1b study evaluates the combination therapy of rituximab, acalabrutinib, and durvalumab (RAD) in relapsed/refractory PCNSL.

[PATIENTS AND METHODS] The study was conducted with dose escalation (3+3 design) and expansion phases. Acalabrutinib (100 mg) was administered once or twice daily for dose determination; rituximab (375 mg/m²) and durvalumab (1500 mg) were treated every four weeks for up to 8 cycles. Primary endpoints assessed safety, tolerability, and the recommended phase 2 dose; secondary endpoints evaluated treatment responses and survival outcomes.

[RESULTS] Seventeen patients, including 15 with relapsed/refractory diseases, were enrolled between February 2021 and April 2024. One patient was unevaluable. No dose-limiting toxicities (DLTs) were observed in the 4-week observation period for 6 evaluable patients at dose levels 1 and 2. In the expansion cohort, 10 additional patients received dose level 2. Treatment-related adverse events (AEs) occurred in 14 patients (82%), with 59% experiencing grade 3/4 events, mainly including neutropenia, skin reactions, and transaminitis. Among 16 evaluable patients, the overall response rate was 62.5%, and complete response rate was 12.5%. All responders received dose level 2. Median overall survival (OS) and progression-free survival (PFS) were 11.9 and 4.3 months, respectively. Improved outcomes were observed for responders versus non-responders (OS, 20.6 vs. 10.2 months; PFS, 5.2 vs. 2.1 months).

[CONCLUSIONS] The RAD regimen is feasible for treating PCNSL patients and shows potential as a therapeutic option. Further large-scale trials are needed to confirm its clinical efficacy.